Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rudwaleit

Showing results (61-70 of 136) with videos related to

Pageof 14
Sort By:
Zeitschrift Fur Rheumatologie|June 27, 2003
[Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany]J Brandt, G Westhoff, M Rudwaleit, et al.
Rheumatology (Oxford, England)|August 11, 2005
Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximabJ Sieper, X Baraliakos, J Listing, et al.
Annals of the Rheumatic Diseases|July 30, 2008
Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label studyM Rudwaleit, E Rødevand, P Holck, et al.
Annals of the Rheumatic Diseases|March 27, 2004
Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitisJ Brandt, J Listing, J Sieper, et al.
Zeitschrift Fur Rheumatologie|November 2, 2004
[Measurement of quality of life in patients with active ankylosing spondylitis being treated with infliximab-a comparison of SF-36 and SF-12]H Haibel, M Niewerth, J Brandt, et al.
Arthritis and Rheumatism|January 20, 1998
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donorsJ Braun, M Bollow, G Remlinger, et al.
The Journal of Rheumatology|April 29, 1998
Increased frequency of Sjögren's syndrome in patients with spondyloarthropathyJ Brandt, M Rudwaleit, U Eggens, et al.
The Journal of Rheumatology|October 1, 1996
Interethnic differences in the association of tumor necrosis factor promoter polymorphisms with systemic lupus erythematosusM Rudwaleit, M Tikly, M Khamashta, et al.
Clinical and Experimental Rheumatology|March 15, 2002
Co-occurrence of spondyloarthropathy and connective tissue disease: development of Sjögren's syndrome and mixed connective tissue disease (MCTD) in a patient with ankylosing spondylitisJ Brandt, T Maier, M Rudwaleit, et al.
Annals of the Rheumatic Diseases|March 25, 2000
Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4M Rudwaleit, Z Yin, S Siegert, et al.
Pageof 14

Showing results (61-70 of 136) with videos related to

Sort By:
Pageof 14
Zeitschrift Fur Rheumatologie|June 27, 2003
[Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany]J Brandt, G Westhoff, M Rudwaleit, et al.
Rheumatology (Oxford, England)|August 11, 2005
Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximabJ Sieper, X Baraliakos, J Listing, et al.
Annals of the Rheumatic Diseases|July 30, 2008
Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label studyM Rudwaleit, E Rødevand, P Holck, et al.
Annals of the Rheumatic Diseases|March 27, 2004
Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitisJ Brandt, J Listing, J Sieper, et al.
Zeitschrift Fur Rheumatologie|November 2, 2004
[Measurement of quality of life in patients with active ankylosing spondylitis being treated with infliximab-a comparison of SF-36 and SF-12]H Haibel, M Niewerth, J Brandt, et al.
Arthritis and Rheumatism|January 20, 1998
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donorsJ Braun, M Bollow, G Remlinger, et al.
The Journal of Rheumatology|April 29, 1998
Increased frequency of Sjögren's syndrome in patients with spondyloarthropathyJ Brandt, M Rudwaleit, U Eggens, et al.
The Journal of Rheumatology|October 1, 1996
Interethnic differences in the association of tumor necrosis factor promoter polymorphisms with systemic lupus erythematosusM Rudwaleit, M Tikly, M Khamashta, et al.
Clinical and Experimental Rheumatology|March 15, 2002
Co-occurrence of spondyloarthropathy and connective tissue disease: development of Sjögren's syndrome and mixed connective tissue disease (MCTD) in a patient with ankylosing spondylitisJ Brandt, T Maier, M Rudwaleit, et al.
Annals of the Rheumatic Diseases|March 25, 2000
Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4M Rudwaleit, Z Yin, S Siegert, et al.
Pageof 14